WASHINGTON-The Cellular Telecommunications & Internet Association Thursday announced it signed contracts for phase two of industry-funded health research called for under an agreement with the U.S. Food and Drug Administration.
CTIA, whose previous $25 million research found genetic damage from low-level radio-frequency radiation, said the second phase of research will focus on epidemiology. The trade group said the FDA, in consultation with experts, recommended that phase-two studies evaluate the best epidemiological tools for measuring exposure to radio-frequency (RF) energy from wireless phones.
The studies, costing about $900,000, are expected to be concluded in fall 2005.
